313 related articles for article (PubMed ID: 20816575)
1. Breast cancer predisposition syndromes.
Hemel D; Domchek SM
Hematol Oncol Clin North Am; 2010 Oct; 24(5):799-814. PubMed ID: 20816575
[TBL] [Abstract][Full Text] [Related]
2. Translational advances regarding hereditary breast cancer syndromes.
Gage M; Wattendorf D; Henry LR
J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
[TBL] [Abstract][Full Text] [Related]
3. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
[No Abstract] [Full Text] [Related]
4. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
5. [Molecular genetics of hereditary breast carcinoma].
Hampl M; Chang-Claude J; Schwarz P; Saeger HD; Schackert HK
Zentralbl Chir; 1997; 122(2):67-73. PubMed ID: 9173760
[TBL] [Abstract][Full Text] [Related]
6. Hereditary breast cancer: the era of new susceptibility genes.
Apostolou P; Fostira F
Biomed Res Int; 2013; 2013():747318. PubMed ID: 23586058
[TBL] [Abstract][Full Text] [Related]
7. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
8. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
10. [Genes beyond BRCA1 and BRCA2 for hereditary breast cancer].
Simon K; Geigl JB; Pristauz G
Wien Med Wochenschr; 2010 Nov; 160(19-20):478-82. PubMed ID: 20890790
[TBL] [Abstract][Full Text] [Related]
11. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.
Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; Durocher F;
Fam Cancer; 2007; 6(4):483-90. PubMed ID: 17636424
[TBL] [Abstract][Full Text] [Related]
13. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
14. Practical aspects of genetic counseling in breast cancer: lights and shadows.
Christinat A; Pagani O
Breast; 2013 Aug; 22(4):375-82. PubMed ID: 23673076
[TBL] [Abstract][Full Text] [Related]
15. Routine TP53 testing for breast cancer under age 30: ready for prime time?
McCuaig JM; Armel SR; Novokmet A; Ginsburg OM; Demsky R; Narod SA; Malkin D
Fam Cancer; 2012 Dec; 11(4):607-13. PubMed ID: 22851211
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
17. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
18. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
19. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
20. BRCA in breast cancer: ESMO clinical recommendations.
Balmaña J; Díez O; Castiglione M;
Ann Oncol; 2009 May; 20 Suppl 4():19-20. PubMed ID: 19454451
[No Abstract] [Full Text] [Related]
[Next] [New Search]
